



## Company Overview

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as graft-vs-host disease (GvHD) and NASH.

### **REMINDER: CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries**

Jan 4 2021, 6:00 AM EST

### **CytoDyn Announces Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity**

Dec 31 2020, 12:48 AM EST

### **FDA Accepts Protocol for Adding an Open-Label Extension to CytoDyn's Phase 3 Trial for Severe-to-Critical COVID-19 Patients**

Dec 30 2020, 11:38 PM EST

## Stock Overview

Symbol	CYDY
Exchange	OTCQB
Market Cap	3.16b
Last Price	\$5.28
52-Week Range	\$0.80 - \$10.02

01/14/2021 03:59 PM EST

## Management Team

### **Nader Z. Pourhassan, Ph.D.**

Director, President and CEO

### **Scott A. Kelly, M.D.**

Chief Medical Officer, Head of Business Development and Chairman of the Board

### **Nitya G. Ray, Ph.D.**

Chief Technology Officer - Head of Process Sciences, Manufacturing & Supply Chain

### **Michael D. Mulholland**

Chief Financial Officer

### **Brian Brothen**

Senior Vice President, Global Oncology

### **Mahboob U. Rahman, M.D., Ph.D., FACR**

Chief Scientific Officer

---

## CytoDyn Inc.

1111 Main Street  
Suite 660  
Vancouver, WA 98660

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.